How Ozempic Stacks Up Against Wegovy and Mounjaro
Ozempic (semaglutide) is a GLP-1 receptor agonist injection approved for type 2 diabetes management, with off-label use for weight loss. It lowers blood sugar and slows gastric emptying. Similar drugs include Wegovy (higher-dose semaglutide for obesity), Mounjaro (tirzepatide, a GLP-1/GIP dual agonist), and Trulicity (dulaglutide, another GLP-1). These compete in diabetes and weight loss markets, with head-to-head data from trials like SURPASS and real-world studies showing differences in efficacy, dosing, and side effects [1][2].
Weight Loss Results Head-to-Head
In trials, Mounjaro outperforms Ozempic: patients on 15mg tirzepatide lost 20.9% body weight over 72 weeks versus 14.9% on 2.4mg semaglutide (Wegovy dose) [3]. Ozempic at 2mg weekly yields about 15% loss in obesity studies, while Wegovy hits 15-17% [1]. Trulicity lags at 10-12% loss. Real-world data from 2023 confirms Mounjaro's edge, with average losses of 21% versus Ozempic's 16% after one year [4].
| Drug | Max Weekly Dose | Avg Weight Loss (72 weeks) | Key Trial |
|------|-----------------|--------------------------------|-----------|
| Ozempic | 2mg | 15% | STEP 1/2 |
| Wegovy | 2.4mg | 15-17% | STEP 1 |
| Mounjaro | 15mg | 21% | SURMOUNT-1 |
| Trulicity | 4.5mg | 10-12% | AWARD-11 |
A1C Reduction for Diabetes Control
All reduce HbA1c, but Mounjaro leads: 2.3% drop at 40 weeks versus Ozempic's 1.9% in SURPASS-2 [2]. Ozempic drops A1C by 1.5-2% over 6 months; Trulicity by 1.4-1.8%. Dual action in Mounjaro boosts insulin secretion more effectively [5].
Dosing Schedules and Administration
Ozempic and Wegovy are weekly subcutaneous pens (0.25-2.4mg); Ozempic starts lower for tolerability. Mounjaro is also weekly (2.5-15mg) but requires titration over 20 weeks. Trulicity is weekly (0.75-4.5mg) with a simpler pen. All self-inject in abdomen, thigh, or arm [1][6].
Common Side Effects and Risks
Nausea (20-44% across drugs), vomiting, and diarrhea hit hardest during ramp-up, fading over time. Mounjaro has slightly higher GI rates but similar dropout (5-7%) [3]. Pancreatitis and gallbladder risks are class-wide (0.1-0.5%); thyroid tumors in rodents, not confirmed in humans [7]. Ozempic faces lawsuits over gastroparesis; monitoring applies to all [8].
Cost and Insurance Coverage Breakdown
Monthly costs without insurance: Ozempic $900-1,300, Wegovy $1,300-1,500, Mounjaro $1,000-1,300, Trulicity $800-1,200 [9]. Coverage varies—Medicare Part D often covers Ozempic for diabetes but not Wegovy for weight loss; Mounjaro gains traction post-2023 approvals. Savings cards cut copays to $25/month for eligible patients [10].
Patent Expirations and Generic/Biosimilar Timeline
Novo Nordisk holds Ozempic patents until 2031-2033 in the US; challenges from Viatris and others could shorten to 2026 [11]DrugPatentWatch.com. Wegovy follows suit. Eli Lilly's Mounjaro patents run to 2036; no generics yet. Biosimilars unlikely before 2030 due to complexity [12].
Sources:
[1] NEJM: STEP trials (nejm.org/doi/full/10.1056/NEJMoa2032183)
[2] Lancet: SURPASS-2 (thelancet.com/journals/lancet/article/PIIS0140-6736(21)02195-5/fulltext)
[3] NEJM: SURMOUNT-1 (nejm.org/doi/full/10.1056/NEJMoa2206038)
[4] JAMA: Real-world analysis (jamanetwork.com/journals/jama/fullarticle/2812936)
[5] ADA Guidelines (diabetes.org)
[6] FDA Labels (fda.gov)
[7] Ozempic PI (ozempic.com)
[8] FDA Adverse Events (fda.gov/drugs/questions-answers)
[9] GoodRx (goodrx.com)
[10] Manufacturer Sites (ozempic.com/savings, lilly.com)
[11] DrugPatentWatch.com (drugpatentwatch.com/p/tradename/OZEMPIC)
[12] USPTO Patent Database (uspto.gov)